A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Completed

Conditions studied: Myelofibrosis

In brief

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Key facts

Study ID

NCT05444972

Run by

AbbVie

People needed

998

Starts

2022-08-23

Expected to finish

2023-11-14

Last updated by the study team

2023-12-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
• Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

You may not qualify if…

• Having received MF treatment in a clinical trial setting.

Where it is running

• Ospedale Belcolle /ID# 245726 — Viterbo, Italy
• UAB Comprehensive Cancer Center /ID# 252767 — Birmingham, Alabama, United States
• Wellness Oncology & Hematology /ID# 255591 — West Hills, California, United States
• Brigham & Women's Hospital /ID# 254312 — Boston, Massachusetts, United States
• Gabrail Cancer Center Research /ID# 252768 — Canton, Ohio, United States
• Instituto FIDES /ID# 245526 — La Plata, Buenos Aires, Argentina
• Hospital Italiano de Buenos Aires /ID# 244373 — Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires, Argentina
• Fundaleu /Id# 244371 — Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, Argentina
• Townsville University Hospital /ID# 246585 — Douglas, Queensland, Australia
• Royal Adelaide Hospital /ID# 246583 — Adelaide, South Australia, Australia
• Fiona Stanley Hospital /ID# 246584 — Murdoch, Western Australia, Australia
• Royal Perth Hospital /ID# 246586 — Perth, Western Australia, Australia
• Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 247394 — São Paulo, São Paulo, Brazil
• Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 247392 — São Paulo, Brazil
• St. Paul's Hospital /ID# 249719 — Vancouver, British Columbia, Canada
• Nova Scotia Health /ID# 248393 — Halifax, Nova Scotia, Canada
• Juravinski Cancer Centre /ID# 251334 — Hamilton, Ontario, Canada
• Princess Margaret Cancer Centre /ID# 249748 — Toronto, Ontario, Canada
• CSSS Alphonse-Desjardins, CHAU de Levis /ID# 250449 — Lévis, Quebec, Canada
• CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 250563 — Montreal, Quebec, Canada
• Jewish General Hospital /ID# 250674 — Montreal, Quebec, Canada
• Organizacion Clinica Bonnadona -PREVENIR S.A.S. /ID# 244589 — Baranquilla, Atlántico, Colombia
• Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 246108 — Bogota DC, Cundinamarca, Colombia
• Fundacion Santa Fe de Bogota /ID# 244588 — Bogota, Cundinamarca, Colombia
• ASST Sette Laghi /ID# 245443 — Varese, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.